RxDoctor Payments Data

Monica Barfield

Family · Port Saint Joe, FLNPI 1225538390

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 63 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$418
  • Lilly USA, LLC$340
  • AbbVie$147
  • Medtronic$113
  • Exact Sciences$103
  • Amgen$41
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$43,734
Medicare patients
133
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide29$36,145
OzempicSemaglutide34$35,533
JardianceEmpagliflozin36$31,770
Tresiba Flextouch U-200Insulin Degludec17$18,727
FarxigaDapagliflozin Propanediol22$17,346
QuliptaAtogepant11$12,606
Breo ElliptaFluticasone/Vilanterol18$7,450
GlyxambiEmpagliflozin/Linagliptin12$6,897
Levothyroxine Sodium132$1,375
Testosterone Cypionate18$1,269
Esomeprazole Magnesium17$934
Potassium Chloride48$860
Atorvastatin Calcium83$856
Losartan Potassium99$806
Albuterol Sulfate HfaAlbuterol Sulfate23$778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$29$38,66748 claims
Lilly USA, LLCTrulicity$340$36,14529 claims
Novo NordiskOzempic$418$35,53334 claims
AstraZenecaFarxiga$12$17,34622 claims
AbbVieQulipta$147$12,60611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Port Saint Joe

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →